Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > Algernon NeuroScience, a subsidiary of Algernon Pharmaceutic
View:
Post by stockpatrol on Jan 27, 2023 2:12pm

Algernon NeuroScience, a subsidiary of Algernon Pharmaceutic

Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has begun a Phase 1 clinical stroke study of DMT in the Netherlands, using a single-escalating dose design to determine a safe, non-psychedelic dose.
 
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-subsidiary-algernon-neuroscience-230000040.html
Be the first to comment on this post